Previous 10 | Next 10 |
home / stock / phguf / phguf news
The European Medicines Agency (EMA) validated Pharming's ( NASDAQ: PHAR ) application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS). The company's marketing authorisation a...
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib Canada NewsWire Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlan...
Pharming Group N.V. press release ( OTCPK:PHGUF ): 9M GAAP EPS of $0.04. Revenue of $151M (-8.0% Y/Y). 2022 Outlook: Single digit growth in Group revenues from RUCONEST® sales. Quarterly fluctuations are expected. Subject to a positive outcome from the F...
Pharming Group N.V. (PHGUF) First Half 2022 Earnings Conference Call August 04, 2022 7:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Jeroen Wakkerman – Chief Financial Officer ...
The following slide deck was published by Pharming Group N.V. in conjunction with their 2022 Q2 earnings call. For further details see: Pharming Group N.V. 2022 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. press release ( OTCPK:PHGUF ): 1H GAAP EPS of $0.03. Revenue of $96.8M (+3.9% Y/Y) misses by $2.43M . For the remainder of 2022, we expect: Single digit growth in Group revenues from RUCONEST® sales, driven by the US and expanded EU markets...
Pharming Group N.V. (PHGUF) Q1 2022 Earnings Conference Call May 12, 2022, 07:30 AM ET Company Participants Sijmen de Vries - CEO Jeroen Wakkerman - CFO Anurag Relan - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainright Hartaj Singh - Oppenheimer & Co. Christ...
Pharming Group N.V. press release (OTCPK:PHGUF): Q1 GAAP EPS of $0.005. Revenue of $46.6M (+6.9% Y/Y) beats by $0.06M. For further details see: Pharming Group N.V. GAAP EPS of $0.005, revenue of $46.6M beats by $0.06M
Pharming Group N.V. (PHGUF) Full Year 2021 Earnings Conference Call March 17, 2022 9:00 AM ET Company Participants Sijmen Vries - Executive Director and Chief Executive Officer Jeroen Wakkerman - Chief Financial Officer Anurag Relan - Chief Medical Officer Conference Call Participants Hartaj ...
Pharming Group N.V. press release (OTCPK:PHGUF): FY GAAP EPS of €0.02. Revenue of €198.9M (-6.3% Y/Y). For further details see: Pharming Group N.V. GAAP EPS of €0.02, revenue of €198.9M
News, Short Squeeze, Breakout and More Instantly...
Pharming Group Nv Ord Company Name:
PHGUF Stock Symbol:
OTCMKTS Market:
Pharming Group Nv Ord Website:
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024. ...
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New ...
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposa...